483s and Warning Letters Point to Inadequate Quality Oversight
Ajay Babu Pazhayatil
Advertisement
Ajay Pazhayattil is a management consultant. (ajpazha@gmail.com). He has held key management roles with brand name, generic, and contract manufacturing pharmaceutical organizations.
Articles by Ajay Babu Pazhayatil
Production and process controls, organization and personnel were the top problems found, while packaging and labelling citations increased in 2017 and 2018.
Advertisement
Latest Updated Articles
Lessons from FDA 483s and cGMP Inspection DataPublished: October 2nd 2019 | Updated:
- Solving Pharma’s Quality Unit Identity Crisis
Published: July 2nd 2020 | Updated:
Advertisement
Advertisement
